Innovative technology based on phages and data, developed to eliminate specific bacteria.
Our production process is carried out according to pharmaceutical quality standards with exceptional yields.
Our production process is carried out according to pharmaceutical quality standards with exceptional yields.
Our HQ in Santiago, Chile, occupies four floors in the UC Anacleto Angelini Innovation Center. It’s a dynamic and collaborative space with infrastructure meeting international standards.
Equipped with cutting-edge technology, our state-of-the-art laboratories seamlessly advance from diagnosis to producing powerful bacteriophage solutions. These high-tech facilities and equipment allow precise and effective operation across all our processes.
Our multidisciplinary teams utilize these resources to innovate, ensuring seamless integration of science and technology within our advanced infrastructure.
Our team of real-time PCR and WGS specialists can process our clients’ samples, sequence DNA libraries, and identify the problematic bacteria in 25 days. We implement new technologies, processes, and top-level team players to generate comprehensive profiles of target bacteria.
Our team of bioinformaticians with extensive computational biology, genomics, and data science experience reduced the time of analysis from 12 months to 10 hours through new scripts, parallelization, and automation.
In this step, the team isolates and characterizes the genomics, kinetic parameters, and physicochemical properties of new phages. Using the double-layer agar technique they test the phages with the potential to interact with the problem bacteria from a client. We have a huge library of characterized bacteriophages.
Our AI team developed proprietary pipelines that accurately predict the target bacteria’s lytic susceptibility against a phage. These workflows help us select the best candidates for a phage cocktail. To that end, our team characterizes the bacteria’s genome, the phage’s genome, and historical data detailing interactions between phages and bacteria.
The best-performing phages are next tested through quantitative assays against the client’s bacterial collection. The designed cocktails are evaluated quantitatively in vitro, and the most effective phages in terms of lytic activity will compose the phage cocktail.
Our new cocktail prototypes are formulated to minimize modifications to our clients’ SOPs. The formulations consist of excipients that must meet the following criteria:
Our Manufacturing, Science & Technology team (MSAT) serves as the bridge between Development and Production. They are in charge of standardizing the optimal conditions to scale up the phages comprising a product.
This international team evaluates the efficacy of our products under real conditions as well as the productive parameters. They go wherever our clients are and assist in setting up the product implementation.
We house the first cost-efficient phage manufacturing facility in the world. Through our manufacturing team, we produce bacteriophage cocktails with immense scalability. Additionally, the yields we obtain with our liquid zootechnical additives allow us to administer them to millions of animals each year.
Our operations team ensures adherence to good manufacturing practices and other relevant standards by implementing and maintaining quality assurance systems at each development and production stage. Additionally, the team manages the logistics of transporting and distributing biotechnological products, ensuring timely delivery in compliance with transportation regulations.
NAVIGATING DIVERSE MARKETS WITH A DEDICATED TEAM OF SPECIALISTS
Our global regulatory affairs team makes sure that our products are approved by the regulatory authorities of each target market.
Bacteriophages are viruses with the ability to infect and destroy specific bacteria. They are abundantly and diversely present in the environment and inhabit the gastrointestinal tract of humans and animals, where they play an important role in regulating the diversity and population of different bacteria.
Bacteriophages do not contain toxic or harmful elements for health, development, or reproduction. During product development, we select bacteriophages free of antibiotic-resistant genes.
Our platform allows for historical and real-time tracking of critical metrics and key data for each project based on its performance.